[Sympathetic reinnervation of the transplanted heart. Study using iodine-123 labeled meta-iodobenzylguanidine]. / Reinervación simpática del corazón trasplantado. Estudio realizado con metayodobenzilguanidina marcada con yodo-123.

INTRODUCTION AND OBJECTIVES: Metaiodobenzylguanidine (MIBG) is an analogue of norepinephrine and its cardiac uptake shows sympathetic innervation. During the heart transplantation the allograft becomes completely denervated. The present study was conducted to assess the evolution of sympathetic re-innervation after transplantation, and to related re-innervation with functional status. PATIENTS AND METHODS: We studied 31 patients from 6 months to 12 years after transplantation by 123I-MIBG studies to evaluate re-innervation and by rest/exercise radionuclide ventriculography to evaluate cardiac function. Myocardial MIBG uptake was quantified by calculating a heart-to-mediastinum ratio (HMR). An HMR > 1.8 was considered normal, moderate between 1.8 and 1.6, mild between 1.6 and 1.3, and absent < 1.3. RESULTS: HMR correlated with time after transplantation (r = 0.607; p < 0.001). HMR of patients studied after 2 years of transplantation was significantly higher (1.62 +/- 0.2 vs 1.34 +/- 0.2; p < 0.05). MIBG uptake was in the anterior region in 3 patients, in the antero-lateral region in 25, and in the antero-lateral and septal regions in 3. From a functional point of view, peak filling rate at exercise was higher in patients studied 2 years after the transplantation (2.7 +/- 0.8 edv/s vs 2.16 +/- 0.5 edv/s; p = 0.02). These patients also showed a higher increase of heart rate with exercise (p < 0.005 vs p < 0.01). CONCLUSIONS: Sympathetic re-innervation increase with time after heart transplantation, and is more frequently seen 2 years after transplantation. Sympathetic re-innervation first appears in the anterior or the antero-lateral regions. A complete re-innervation of the transplanted heart does not occur 12 years after transplantation.

[Evaluation of myocardial viability using perfusion cardiac SPECT. 201-thallium rest/redistribution, 201-thallium rest/reinjection and technetium 99m tetrofosmin rest/postnitrates]. / Valoración de la viabilidad miocárdica mediante SPET cardíaco de perfusión. Talio-201 reposo/redistribución, talio-201 reposo/reinyección y tecnecio-99m tetrofosmina reposo/posnitratos.

INTRODUCTION AND OBJECTIVES: It has been demonstrated that nitrate administration enhances the detection of myocardial viability in thallium-201 and technetium-99m sestamibi myocardial perfusion studies. The aim of this study was to assess the influence of nitrate administration on technetium-99m tetrofosmin myocardial uptake in patients with coronary artery disease and left ventricular dysfunction. PATIENTS AND METHODS: Twenty eight patients with coronary artery disease, previous myocardial infarction and left ventricular ejection fraction < 40% underwent, within 48 hours, rest/postnitroglycerin (0.4 mg sublingually) technetium-99m tetrofosmin single photon emission tomography (SPET), comparing these results with that of thallium-201 rest/redistribution SPET in 13 patients (first group) and with that of thallium-201 rest/reinjection SPET in the other 15 patients (second group). Tomograms based on the 3 spatial planes were divided into 15 segments and regional tracer uptake was quantitatively analysed. Viability was defined as presence of tracer uptake > or = 50% of peak activity. RESULTS: The percentage of peak activity at rest or after nitrate administration of technetium-99m tetrofosmin correlated, with that of thallium-201, at rest and after redistribution or reinjection (r = 0.8; p < 0.001). On resting technetium-99m tetrofosmin studies 167 of the 420 segments that were analysed had < 50% of peak activity. 14.5% of these segments showed reversibility after nitrate administration, with an increase in 99mTc-tetrofosmin uptake from 45 +/- 5% to 55 +/- 4% of peak activity (p = 0.001), in the first group, and from 40 +/- 9% to 57 +/- 9% of peak activity (p = 0.003), in the second group. Overall agreement between rest/postnitroglycerin technetium-99m tetrofosmin SPET studies and rest/redistribution or rest/reinjection thallium-201 SPET studies, regarding the presence of myocardial viability, was 87% and 90%, respectively. All except one reversible segments on tetrofosmin studies after nitrates had viability criteria on thallium studies. CONCLUSIONS: Nitrate administration at rest enhances the detection of myocardial viability using technetium-99m tetrofosmin SPET, correlating with viability criteria observed on thallium studies. It represents a simple and useful technique in the assessment of myocardial viability.